Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study | Zendy

Raffaella Lionetti | Zendy; Paola Piccolo | Zendy; Ilaria Lenci | Zendy; Massimo Siciliano | Zendy; Ubaldo ViscoComandini | Zendy; A. De Santis | Zendy; Maurizio Pompili | Zendy; Martina Milana | Zendy; Chiara Taibi | Zendy; Serena Dell’Isola | Zendy; Marzia Montalbano | Zendy; Claudio Maria Mastroianni | Zendy; Paola Begini | Zendy; Anna Rosa Garbuglia | Zendy; M. Angélico | Zendy; Gianpiero D’Offizi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study

Author(s) -

Raffaella Lionetti,

Paola Piccolo,

Ilaria Lenci,

Massimo Siciliano,

Ubaldo ViscoComandini,

A. De Santis,

Maurizio Pompili,

Martina Milana,

Chiara Taibi,

Serena Dell’Isola,

Marzia Montalbano,

Claudio Maria Mastroianni,

Paola Begini,

Anna Rosa Garbuglia,

M. Angélico,

Gianpiero D’Offizi

Publication year - 2019

Publication title -

annals of hepatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.705

H-Index - 53

eISSN - 2659-5982

pISSN - 1665-2681

DOI - 10.1016/j.aohep.2018.09.005

Subject(s) - daclatasvir , sofosbuvir , medicine , ribavirin , tolerability , gastroenterology , cirrhosis , hepatitis c , hepatitis c virus , adverse effect , hepatology , virology , virus

Cirrhotic patients with hepatitis C virus genotype 3 infection show unsatisfactory outcomes after 12 weeks' treatment with direct antiviral agents. The National Italian Drug Agency allows 24 weeks of therapy in difficult-to-treat patients, including genotype 3 cirrhotics. Aim of this study was to evaluate efficacy and safety of a 24-week course of sofosbuvir plus daclatasvir±ribavirin in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research